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Abstract
A wide range of malignant and nonmalignant diseases require hematopoietic stem cell
transplantation (HSCT) as last resort therapeutic approach. Graft versus host disease
(GVHD), which is one of the major causes of transplant-related mortality, is minimized
whenever increased matching of human leukocyte antigens (HLAs) between donor and
recipient is present. Suitable donor selection is determined with the utilization of HLA
typing. HLAs are highly polymorphic glycoproteins encoded by a region of genes
known as the major histocompatibility complex (MHC). Their biological function is to
present antigenic peptides to T lymphocytes. However, they also play important role in
HSCT acceptance/rejection. During the previous years, various techniques have been
acquired in order to  better  characterize the HLA profile  of  transplant  donors  and
recipients. This effort is particularly challenging due to MHC size, but most importantly
due to high sequence variability in specific regions of the respective genetic loci, between
individuals. Initially, HLA typing was performed using serological typing, hybridiza-
tion techniques, and restriction fragment length polymorphism (RFLP) approaches.
Later on, polymerase chain reaction (PCR) based techniques and direct sequencing
(dideoxy-based Sanger sequencing) capillary electrophoretic analyses arose.  Nowa-
days, 2nd and 3rd generation sequencing (NGS) technologies show great potential in
effectively identifying these polymorphic regions.
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1. Introduction
The past few decades have been detrimental for understanding the mechanism of appearance
and  evolution  of  many  myeloid  and  lymphoid  diseases.  Previous  immunobiology  and
molecular biology techniques along with most current sequencing technologies and their
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implementation in molecular diagnostics altogether contributed toward characterizing such
conditions.
Novel pharmaceutical approaches, such as targeted therapies, optimized chemotherapy
regimens, radiotherapy, and others have been developed. Yet, many of these diseases still
present poor survival outcomes. In such cases, hematopoietic stem cell transplantation (HSCT)
is considered as final resort therapeutic approach, whenever all other options have failed [1].
The success of HSCT depends on various factors that should be taken into consideration in
advance. Reduced immunological reaction is such a major factor. This is only accomplished
when donor and recipient of the graft are immunologically compatible. During the previous
decades, immunology and molecular biology techniques have been moving toward delineat-
ing the biological mechanism of this compatibility.
During the past few years, the advent of high throughput sequencing technologies has helped
move toward this direction with a much faster pace. In this chapter, we will review the past,
present, and future of these technologies in this particular area of research.
2. Transplantation as a therapeutic approach
HSCT offers potentially curative therapy for patients suffering from various congenital or
acquired malignant or nonmalignant lymphohematopoietic diseases.
These mainly include myeloid malignancies such as myeloproliferative neoplasms (MPNs), in
particular myelofibrosis (MF). Others include myelodysplastic syndromes (MDS), myelodys-
plastic syndromes/myeloproliferative neoplasms (MDS/MPNs), chronic and acute myeloid
leukemias (CML and AML).
Also, lymphoid diseases such as acute lymphoblastic leukemia (ALL), chronic lymphocytic
leukemia (CLL), Hodgkin, and non-Hodgkin lymphomas, as well as various types of anemias
(Fanconi’s anemia, severe aplastic anemia) are highly ranked among [2, 3].
2.1. Factors affecting the decision and outcome of HSCT
Several factors should be taken into account in order to estimate the benefit/risk of HSCT
compared to other treatment options, such as chemotherapy [4].
These include disease characteristics, age along with related comorbid conditions and donor
availability, followed by race, socioeconomic status and financial fitness.
These can be widely viewed as pretransplantation, transplantation-associated and post-
transplantation risk factors, although they cannot be classified in such a way, because the
transplantation protocol is affected by pre-transplantation conditions and they may both affect
post-transplantation events. The latest comprise of graft-versus-host disease (GVHD), infec-
tions, and disease relapse.
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Donor suitability is a major issue affecting the course of HSCT and shall be thoroughly
analyzed.
2.1.1. Donor suitability
2.1.1.1. Human leukocyte antigen (HLA) system
It is well established that donor suitability is mainly dictated by the genomic loci of major
histocompatibility complex (MHC), located on the short arm of chromosome 6 in humans. This
highly polymorphic genetic system encodes for the major histocompatibility antigens that
comprises the human leukocyte antigen (HLA) system.
These cell surface antigens where first characterized using allo-antibodies (allo-Abs) against
leukocytes. Although they are clinically important in HSCT, their primary biological function
is the regulation of immune response [5].
Only 30% of patients have HLA-matched-sibling donor (HLA-MSD) which is the gold
standard for allogeneic hematopoietic stem cell transplantation (allo-HSCT). The remaining
70% relies on alternative sources of stem cells.
These include suitable volunteer HLA-matched-unrelated donors (HLA-MUD), one-locus
HLA-mismatched-unrelated donors (HLA-mmUD), HLA-haploidentical donors (HLA-
haplo) (half matched donor, typically a parent or other relative), or umbilical cord blood (UCB)
units [6–8].
The success of HSCT highly depends on the HLA compatibility between graft and patient.
This is because recognition of HLA allelic differences by T lymphocytes of the patient increases
the risk of graft rejection, GVHD, slow or incomplete immune reconstitution, and consequent
risk of lethal opportunistic infections [9].
Other important prognostic impact factors are age, sex, cytomegalovirus (CMV) serostatus,
and natural-killer (NK) cells allo-reactivity [6].
2.1.1.2. Killer inhibitory receptor (KIR) types
KIR types comprise yet another genetic characteristic of donor that affects transplantation
outcomes during allo-HSCT.
NK cells are lymphoid cells of the innate immunity that contribute to GVT, but not GVHD.
Their function is characterized by interaction of surface receptors with their cognate ligands
on target cells. KIRs are such receptors whose genetic loci constitutes of multiple genes that
encode for them, just like the respective genetic loci of HLA genes.
Also, there is considerable genetic diversity in the KIR genetic locus, like with MHC.
Upon binding of some of the KIRs with their ligands, NK cell function is inhibited, while other
KIRs promote activation of NK cells after engagement with their cognate ligand.
Most of the KIR-ligands are HLA-class I molecules.
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KIRs can be subdivided into two main categories based on the strength of their affinity to the
ligands. It has been observed that Group A binds more effectively than group B.
KIRs seem to play important role in transplantation outcome. Transplant recipients missing
KIR-ligands, especially in the absence of allo-reactive T cells (e.g., in T-cell-depleted HLA-
haplo HSCT) were proven to present decreased rate of disease recurrence and improved
survival.
To conclude, the presence of activating KIR genes in the donor favorably affects recurrence
rates in myeloid, but not lymphoid neoplasms [10].
3. The human leukocyte antigen system
3.1. Organization of the human MHC genetic loci
As previously described, the human MHC, also known as HLA, located on the short arm of
chromosome 6 (6p21), is a highly polymorphic gene dense genetic system. The HLA gene
products are globular glycoproteins, each composed of two noncovalently linked chains. These
proteins are ligand molecules, cell surface receptors and other factors involved in inflammatory
response; recognition, processing, and presentation of foreign antigens to T cells, as part of the
adaptive immune response; and also in innate immunity.
In addition to protein encoding genes, the MHC genetic loci contains pseudogenes and also
transposon, retro-transposon and regulatory elements [11].
The HLA system comprises of almost 220 genes, with 21 of them being genes of major interest.
These are located within genomic location 6p21.3 and their protein products mediate human
response to infectious disease and influence the outcome of cell and organ transplants [12].
The human MHC genetic loci are divided in three distinct regions.
The class I region consists of genes that encode for HLA class I molecules, namely the HLA-
A, HLA-B, and HLA-C (and also the nonclassical HLA-E, HLA-F, HLA-G, and the class I-like
molecules MIC-A and MIC-B). These are expressed on the surface of almost all nucleated cells
and are responsible for presenting intracellular derived peptides to CD8+ T cells.
The class II region includes genes that encode for HLA class II molecules, namely HLA-DR
(DRA, DRB1, and depending on the haplotype the DRB3, DRB4, or DRB5), HLA-DQ (DQA1,
DQB1), and HLA-DP (DPA1, DPB1) molecules. These are expressed in professional antigen
presenting cells (APCs), such as macrophages, dendritic cells and B lymphocytes, in order to
present extracellular derived peptides to CD4+ T cells.
Located between these two, is the class III region that contains non-HLA genes with immune
function, such as complement components (C2, C4, factor B), cytokines, tumor necrosis factor
(TNF), and lymphotoxins and heat shock proteins [13].
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3.2. HLA nomenclature
The complexity of HLA requires the development of a more sophisticated nomenclature for
locating the specific genomic region addressed each time:
1. HLA prefix: the HLA-prefix designates the MHC gene complex.
2. Genetic loci: following capitals indicate the specific genomic region (A, B, C, D, etc.) and
subregion if available (DR, DQ, DP, DO, DN, etc.).
3. Genetic loci encoding for specific class II alpha and beta peptide chains are indicated next
(DRA1, DRA2, DRB1, DRB2, etc.).
4. Field 1 (two-digit typing) provides the allele group (or allele family), which is designated
by two digit that define the serologic group reactivity.
5. Following the allele family, separated by a colon (:), is field 2 (four-digit typing) which
provides the specific HLA allele (HLA protein).
6. The following digits, also separated by colons, contain other scientifically important
information.
i. Field/digit 3. Alleles that differ only by synonymous nucleotide substitutions within
the coding sequence (CDS) are distinguished by the use of the fifth and sixth digits
(six-digit typing).
ii. Field/digit 4. Alleles that differ only by sequence polymorphisms in noncoding
regions (e.g., introns) are distinguished by the use of the seventh and eighth digits
(eight-digit typing). This is level of resolution distinguishes the specific HLA genome
sequence.
7. Last is the suffix that denotes changes in expression levels of the HLA protein products
[14–16]. An example is presented in Figure 1.
Figure 1. Paradigm of a complete MHC molecule nomenclature where exact information regarding the specific antigen
expressed on the cell surface are enclosed between prefix and suffix information, which concern the type of protein
produced, as well as its expression levels, respectively.
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3.3. The diversity of HLA
The HLA genes located on a single chromosome, meaning the entire set of A, B, C, DR, DQ,
and DP genes, also called a haplotype, are inherited in a typical Mendelian fashion altogether.
So, each parent passes on a specific HLA haplotype to their descendants. This way in 50% of
the cases two siblings are HLA haplo-identical (share one haplotype), whereas siblings with
the same HLA genotype (both haplotypes are the same) or totally different HLA haplotypes
equally share the remaining percentage (25% each).
This first level of genetic variation may be further enhanced with random genetic crossovers
(chromosomal recombination) in the HLA region during meiotic division of gametic cells,
though this is usually uncommon.
Additionally, amino acid variation which is mainly found in the extracellular antigen-binding
grooves, as well as their surrounding regions, on the HLA protein molecules, alters the antigen
binding specificity of the cells. This possibly contributes to enhanced diverse response after
exposure to a variety of environmental infectious and noninfectious agents in the different
areas of the world.
This amino acid variation stems from nucleotide sequence alterations such as single nucleotide
polymorphisms (SNPs), copy number variations (CNVs), insertion/deletion events (InDels),
and inversions, especially within the HLA class I and II gene regions [5, 11, 17].
3.4. HLAs in HSCT: the purpose of HLA typing
It has become clear by now that HLA molecules play an important role in HSCs, the success
of which highly relies on the degree to which donor and recipient are HLA matched. HLA
genotypically identical sibling is the gold standard. Whenever this is not the case, a perfect or
well-matched unrelated donor is preferred over mismatched unrelated donors, haplo-identical
donors and UCB.
Thus HLA matching is especially crucial when it comes to HSCT between unrelated persons.
This is because allo-recognition of HLA allelic differences by T cells is related with acute and
chronic GVHD, impaired engraftment, and higher mortality [12, 18].
To address this issue, molecular typing technologies have evolved substantially in order to
more accurately determine the HLA genotype of both patients and donors, before HSCT. Older
techniques provided limited information compared to more advanced high throughput
sequencing methods, which dramatically increased the list of known HLA alleles. More than
14,000 HLA alleles have been identified, the vast majority of whom is being variants of the
HLA class I genes. These encode for more than 10,000 different HLA proteins [8, 17].
3.5. HLA typing resolution
Levels of HLA typing resolution have been established by expert consortiums. These include:
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• Low-resolution typing, or two-digit typing, is equivalent to serological typing, provides
limited information that correspond to identification of broad families of alleles and is also
called antigen level typing.
• High-resolution typing, is a four-digit typing, which refers to one or a set of alleles that
encode for the same antigen binding site and excludes null alleles (e.g., alleles that are not
expressed on the cell surface).
• Allele level typing (all-digit typing), refers to the exact nucleotide sequence determination
of an HLA gene.
• Other level of resolution correspond to intermediate level of typing (between low and high),
which can define specific allele groups and subtypes.
Today, when adult donor HSCT is considered, the gold standard is high-resolution typing at
the HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 genetic loci (10/10 match). Single
discrepancies for these regions are associated with increased risk of post-transplant compli-
cations, although HLA-DQB1 and in some cases HLA-C mismatches seem to be better toler-
ated, compared to mismatches in the other regions. Also, not all mismatches are of the same
risk, some of them appear to have little or no increased risk, the so called permissive mis-
matches, which will be discussed later on.
HLA-DPB1 and KIR are also taken into account whenever possible. HLA-DPB1 is not tightly
linked to the other genomic regions, so it is more difficult to find a perfect donor (12/12) when
this genetic locus is also taken into account. The positive aspect of this misfortune is the fact
that there are some permissive HLA-DPB1 mismatches that do not impact overall survival
rates in case of perfectly matched donor unavailability (11/12).
Nowadays, HLA-DQA1 and HLA-DPA1 are not taken into account during HLA typing
because of the strong linkage disequilibrium (LD) they present with the corresponding HLA-
DQB1 and HLA-DPB1 loci. LD refers to certain alleles inherited together with increased
frequency than that expected only by chance.
A treatment algorithm has been developed to address the complicated issue of selecting the
fittest available unrelated donor for HSCT:
1. At first, search for 7/8 or 8/8 HLA-A, HLA-B, HLA-C, or HLA -DRB1 allele-matched donor.
2. When many of them are available, look for 9/10 or 10/10 HLA-A, HLA-B, HLA-C, HLA-
DRB1, and HLA-DQB1 matching.
3. If none of the first are available search for suitable, at least 4/6 HLA-A, HLA-B, and HLA-
DRB1, UCB units, with adequate cells dose, ideally NIMA-matched. NIMA-effect refers
to bidirectional trans-placental trafficking of cells, which expose the fetus to the maternal
cells that express both inherited maternal antigens (IMA), as well noninherited maternal
antigens (NIMA), resulting in the development of NIMA-specific responses.
4. When only mismatched donors are available, HLA antibody (Ab) screening/matching
should be performed [8, 13, 15, 18].
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3.6. Seeking for permissive (relatively well-tolerated) HLA mismatches
It is well understood that even single nucleotide substitutions might impact the course of
transplantation significantly either on the aspect of GVHD, engraftment success and transplant
related mortality, delayed immune reconstitution, but not disease relapse.
Of course the extent of their impact is driven not only by the kind of genetic alteration (SNP,
CNV, InDel, inversion), the effect it exerts on the final protein product (synonymous versus
nonsynonymous polymorphisms) and the gene it appears at (HLA class I or II), but also the
exact nucleotide position it is located, since this might affect more or less important amino acid
sequences, regarding the protein’s function.
With the advent of novel sequencing techniques allele level typing provides extensive
nucleotide sequence data, which in correlation with previously available clinical data, is going
to provide significant information in the context of retrospective studies [8, 12, 19].
4. The past and present of HLA typing
HLA genes contain 5–8 exons ranging in length from 4 to 17 kb. Most high-resolution four-
digit HLA typing technologies, mainly sequence-based techniques (SBT) or probe-based
hybridization techniques, primarily focus on deciphering the sequence of the antigen-binding
groove only. This is due to the high cost of complete HLA genotyping and the limited time
interval before HSCT. Thus, only exons 2 and 3 (540 bp) for class I molecules and exon 2 (270
bp) of class II molecules are typically analyzed, providing intermediate-resolution typing.
Before these techniques came into light, less informative serology methods were acquired for
HLA typing. On the other hand, the future seems very promising thanks to the evolution of
sequencing technologies [20].
Next, we will provide a brief review of evolution of the most widely applied techniques for
HLA typing, frequently utilized by clinical laboratories.
4.1. Serological methods
4.1.1. CDC (complement-dependent lympho-cytotoxicity) technique
Lymphocytes incubated with polyclonal sera in the presence of complement, was the first
attempt for determining patient-donor compatibility. CDC utilizes sera from multiparous allo-
immunized women, whose HLA specificity (reactivity against a particular HLA type) is
determined using a panel of lymphocytes of already known HLA type.
From a population of peripheral blood lymphocytes (PBLs), T lymphocytes are used for
determining class I antigens, while B-lymphocytes (professional APCs) are separately isolated
for determining class II antigens. The cells are incubated along with the characterized serum
and complement. Their reactivity is determined based on the lysis of Ab-covered lymphocytes,
from complement components, as shown in Figure 2.
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Figure 2. Example of a serological reaction utilizing the CDC technique. The lysis of the lymphocytes by a serum con-
taining anti-HLA B35 Abs denotes the HLA-B35 positivity of the cells.
The low-resolution two-digit serologic typing this technique offers is further limited by the
availability of sera containing various HLA specificities. However, this method has value in
confirming the presence or absence of an antigen in case of mutations in promoter regions or
genes not otherwise analyzed [5, 18, 21].
A variation of the above technique involves incubation of the donor’s cells with serum from
the patient in the presence of complement. The results are interpreted the same way as
previously described.
Both techniques rely on cell viability in order to be successful and accurate. Also, cell popu-
lations need to be lymphocyte-specific so that the results be interpretable. Samples contami-
nated by other lymphocytes and/or precursor cells lead to inaccuracies [22].
4.1.2. Other serological techniques
FACS overcomes two additional obstacles of the CDC method. The first refers to the positive
reactions mediated through cytotoxic Abs directed against non-HLA molecules (lower
specificity). The second regards positive reactions that are driven only by the complement-
activating Abs, thus failing to detect complement-independent acting donor-specific Abs
(lower sensitivity).
However cell viability dependence is still an obstacle. Combined with its high cost, this
technique is prohibitive for HLA-typing in a routine use by a clinical laboratory.
Solid phase assays, such as ELISA (enzyme-linked immunosorbent assays) and the Luminex
technology, the last utilizing fluorescent dye impregnated beads bound to HLA molecules,
have also been developed for HLA typing. These have mainly, but not exclusively, been studied
in solid organ transplantation studies. In HSCT studies, these techniques mainly focus on HLA-
Ab screening due to the renewed interest on donor-specific Abs (DSA) and their importance
in graft failure [22–27].
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Since molecular methods have proven to be more reliable, we will focus on them for a much
more comprehensive analysis [28].
4.2. Molecular methods
The development and extensive usage of molecular methods soon substituted serologic
techniques, for determination of individuals’ HLA type.
Molecular methods provided higher resolution typing, without the need for preserving
characterized sera of all HLA types, even those not very common ones, and without the
prerequisite of cell viability for test success.
Molecular methods of typing are still the main approaches to HLA typing resolution of low
(two-digit) or intermediate (partial four-digit) level. The four-digit resolution these techniques
offer for analysis of limited but HSCT important loci, contributed to the identification of
serologically indistinguishable variants of HLA class I and II molecules with few, but detri-
mental, amino acid changes.
High-resolution typing at the four-digit level for all HLA loci is an unrealistic goal with these
techniques. Molecular methods mainly focus on identifying polymorphisms in exons 2 and 3
of the class I locus and exon 2 of the class II locus, which are crucial for HSCT, as mentioned
before [5, 18, 29].
4.2.1. PCR/SSP (sequence-specific priming PCR)
Genomic DNA (gDNA) is isolated from the under investigation sample and HLA regions of
interest are amplified using PCR technology.
PCR utilizes in vitro prepared small oligonucleotide sequences (primers or oligos). These
oligos bind to an exact location of a DNvA molecule, according to complementarity rules,
acting as starting points for the production of multiple complementary copies of the inter-
mediate region between a pair of them (amplification). More primers per reaction or more
pairs of primers may be included in a single PCR, depending on the purpose of each protocol
[29–32].
Sequence specific PCR (PCR/SSP), whether characterized as allele-specific amplification PCR
(PCR/AS), amplification refractory mutation system PCR (PCR/ARMS) or multiplex PCR,
exploits PCR for the amplification of specific HLA regions with minor alterations in primer
design each time.
The amplification primers are polymorphic-specific, meaning that they only extend and form
a product if the targeted polymorphism exists. The primers are designed in such a way, so that
their 3’ end nucleotide is complementary to the investigated genomic alteration. Thus products
of specific length are produced depending on the polymorphism and the primer design.
Afterward, these are visualized using gel electrophoresis.
This technique might result in no amplification at all if none of the polymorphisms analyzed
exists, thus another set of primers is coamplified. This corresponds to a monomorphic target
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sequence that produces an extra fragment of distinguishable length. The last determines the
quality of DNA and the validity of the technique (successful reaction) [24].
PCR/SSP may become a time and labor intense technique, when not used in a multiplexed
format for the analysis of many polymorphic sites. If multiplex format is preferred, the
conditions for a successful PCR need to be very stringent. Also, this technique is prone to false-
positive bands and false-negative results, especially for degraded samples.
However, this method is especially useful if applied in conjunction with PCR/SSOP (sequence
specific oligonucleotide probes) hybridization typing, providing higher resolution, since it
allows the separate amplification of the two alleles in a heterozygote [28, 33–35].
4.2.2. PCR/SSOP (sequence-specific oligonucleotide probes)
4.2.2.1. Reverse hybridization (reverse dot blot)
The PCR step of SSOP utilizes chemically modified (biotin labeled) primers nonpolymorphic-
specific. Under normal circumstances, meaning the DNA is intact and no random polymor-
phism exists in the 3’ end of a single primer, the biotinylated amplified products (amplicons)
are produced by each primer pair. This way, the primer pair is designed in such a way in order
to produce an amplicon that includes polymorphisms inside its sequence.
The PCR product is afterward incubated with a panel of already known polymorphic HLA
sequence molecules (SSO probes), which are enzymatically poly-thymidine (poly-T) tailed.
This enzymatic tailing enables their prestabilization on a solid surface, usually a nylon
membrane.
The modified amplicon will cross react with only one of these probes (complete complemen-
tarity) during their incubation along with horseradish peroxidase (HRP)-conjugated strepta-
vidin and a chromogenic or chemiluminescent substrate. HRP-conjugated streptavidin binds
on the biotinylated product. In the presence of biotin, HRP enzyme is activated and metabolizes
the substrate in order to emit light signal. This light is device detected and computer analyzed
later on, to determine the polymorphism of the unknown sample, based on position analysis
of the signal, since the stabilization position of each probe on the membrane is previously
known.
As one can conclude the specific sequence of gDNA where the primers will bind, need to be
known in advance. The polymorphisms under investigation also need to be already known,
in order to prepare and stabilize the suitable set of probes.
Interpretation difficulties may arise from less intense, absent or dubious hybridization
patterns, due to poor-quality and low-quantity DNA amplification or background signals due
to poor membrane washing or temperature variation during hybridization.
Another limitation of this technique is the fact that the extremely polymorphic HLA alleles,
especially those of class I, are impossible to analyze due to the very large number of probes
such a design would require. However, as a general rule, wider number of probes for every
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HLA loci and larger number of unknown HLA regions investigated provides higher resolution
level [29–31, 36].
4.2.2.2. Direct hybridization (conventional dot-blot)
An alternative to reverse dot-blot PCR-SSOP, is the conventional dot-blot technique, where the
PCR amplified regions are the ones immobilized on the solid surface, and biotin-labeled SSO
probes are incubated along with HRP-conjugated streptavidin and a substrate. The ones that
bind the unknown amplicons emit light of specific wavelength identified in the same manner
as previously described.
In addition to the previously described limitations this technique is also more cumbersome,
since the number of SSOPs required for typing vastly increases, due to the high polymorphic
state of HLA loci [30, 31].
4.2.3. PCR/RFLP (restriction fragment length polymorphism)
RFLP analysis involves digestion of gDNA with endonucleases, one at a time, which cleaved
a specific nucleotide sequence motif, in order to produce fragments of various lengths. This
variation can be detected by Southern blot analysis of the digested fragments. Suitable probes
for detection are either cloned cDNA, or genomic DNA sequences, complementary to mainly
HLA class II regions which were better studied. In fact, this technique was the first that revealed
the incredible variation of HLA class II region.
However, it is cumbersome, it requires a large amount of high molecular weight genomic DNA,
and it can only be applied to regions that bear the respective restriction sites, which is not
always the case and that is why it did not replace serological typing, but was rather used
complementary.
PCR-combined RFLP (PCR/RFLP) analysis is an improvement to the previous method. The
amplified HLA region is incubated with a restriction endonuclease that recognizes specific
nucleotide sequence. The digestion reaction is performed whether a polymorphism exists or
not, producing amplicon fragments of various lengths. The products are analyzed by gel
electrophoresis.
However, like RFLP analysis, PCR/RFLP may lead to inconsistencies during HLA typing due
to complex manipulation steps and possible incomplete digestion reactions. Also, this
technique is unable to detect multiple recognition sites simultaneously [29, 33, 36, 37].
4.2.4. PCR/SBT (sequencing-based typing)
Another approach to high-resolution HLA typing is the PCR amplification and subsequent
direct sequencing of previously described class I and II exons. Dideoxy-based Sanger sequenc-
ing, using capillary electrophoresis, provides increased reliability especially when applied
after SSO or SSP.
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The two alleles of heterozygous samples, which represent a substantial source of ambiguities,
are usually sequenced separately following SSO or SSP typing, thus increasing the resolution
of possible genotypes [29, 37].
This technique, although more automated, easier to implement and less prone to technical and
interpretational errors, is less sensitive than others, like SSO, which when optimized provide
more accurate results and less ambiguous results [24].
4.2.5. PCR/RSCA (reference strand-mediated conformational analysis)
Although PCR/SBT is able to detect unknown HLA polymorphisms, the problem of not being
entirely able to resolve novel arrangements of known polymorphisms, also known as ambi-
guity, can be overcome by the PCR/RSCA technique [19].
PCR/RSCA can achieve high-resolution results without the ambiguities seen in the previously
described methods. This technique is based on the principles that DNA fragments that differ
in nucleotide composition exhibit different motilities after separation by nondenaturing
polyacrylamide gel electrophoresis (PAGE). The amplified alleles under investigation are
hybridized with a fluorescent labeled reference strand, forming a double stranded DNA with
unique conformation (double strand conformation analysis; DSCA).
PCR/RSCA is capable of resolving even single base alterations and of course, identification of
new mutations thanks to the different spatial structure of the newly formed DNA-probe
duplexes [38].
5. The present and future of HLA typing
We will mainly focus our review on the second and third generation of sequencers which made
their way into many aspects of personalized medicine, genetic diseases research and clinical
diagnostics, providing reduced hands on time, higher throughput, higher sensitivity and lower
cost-per-base compared to Sanger sequencing and other techniques.
Transplantation success depends on many factors; one of them being the similarity of the
sequence of genes, mainly those of the MHC genetic loci, as long as others (minor histocom-
patibility complex; KIR, MIC-A, and MIC-B), between donor and recipient of the graft.
Characterization of these genomic sequences in both persons before HSCT is of great impor-
tance for selecting the most appropriate transplant, in order to avoid GVHD, enhance engraft-
ment rate and assist GVT effect [38–40].
5.1. The second generation of sequencers (typically named next-generation sequencers;
NGS)
When it comes to HLA typing, NGS technology overcomes many of the cons older techniques
present.
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First of all, it allows setting the phase of linked polymorphisms within the amplicons produced
during the first steps of the technique, meaning that it helps determine in which of the two
alleles, the identified groups of variants, belongs to. In heterozygous samples this is a major
concern with older techniques, as recognized polymorphisms resulted in two or more different
allele combinations that produced identical consensus sequences.
It also allows determination of a large number of sequences in a single reaction. This way many
exonic, and also important intronic sequences, can be simultaneously analyzed. The expression
levels of HLA genes are also very important, thus detection of polymorphisms outside of
exonic sequences, within regulatory intronic regions, is also necessary [29, 40].
Another advancement, all NGS systems share, compared to older techniques, is the higher
level of coverage they provide, leading to increased accuracy as previously described.
Coverage refers to the number of times each nucleotide position is read, and later on, success-
fully aligned to a reference genome, during all sequencing runs. The higher the coverage of a
single position, the higher the confidence level of base calling [38].
Many companies rally toward building the fastest, less expensive and more accurate sequenc-
ing system, along with user friendly analyses pipelines, since the huge amount of data
extracted from these machines require extensive bioinformatics knowledge. Algorithms that
deal with a variety of issues concerning data analysis have been developed during the past
few years. Many of these are nicely summarized in the publications from Szolek et al. [41] and
Hosomichi et al. [16], although new algorithms are continuously deployed, with the prospect
of simplifying and making data analysis more precise, for their implementation in everyday
practice of clinical laboratories and biomedical research [42].
NGS, or second-generation sequencing technologies, constitute various strategies relying on
a combination of template preparation, sequencing and imaging followed by in silico genome
alignment and assembly methods. Of them, the most widely utilized, sequencers for HLA
typing, are those of Illumina (MiSeq) and Roche/454 (454 GS FLX Titanium/454 GS Junior) [16].
5.1.1. Library preparation
5.1.1.1. PCR based
The first step the technologies of Roche/454 and Illumina NGS systems usually utilize is a
fragmentation step, where gDNA is digested into smaller fragments, followed by a PCR, for
the amplification of DNA samples. Primers that bind to specific sequences of genomic DNA
(gDNA) are designed, and the intermediate region of interest is enzyme amplified.
This row of events may be reversed, meaning that long range PCR, with the addition of suitable
enzymes and primers, may precede the fragmentation step.
Each primer, except for the gDNA complementary sequence, also includes a number of
additional nucleotides. These mainly comprise of the system-specific adapter sequences and
the multiplex identifier tags (MIDs). The adapters assist the amplicons bind to a solid surface
(either this is a bead or a slide) and provide a universal priming site for sequencing primers.
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MIDs help recognize the individual sample to whom the amplicon sequence generated and
then sequenced, belongs to. This is particularly useful, for discriminating samples’ reads
(demultiplexing), in case more than one samples are prepared and pooled together for
sequencing. This barcoding method is called “amplicon sequencing.”
A variation of this technique, also known as “shotgun sequencing,” utilizes simple primers.
The adapters and MIDs are ligated to the amplified sequences after the PCR and prior to sample
pooling [16, 40].
5.1.1.2. Hybridization based (target enrichment)
Target enrichment utilizes biotin labeled DNA or RNA oligonucleotide sequences (probes)
(55–120 bp) which hybridize to their complementary target region of previously fragmented
gDNA. Streptavidin magnetic bead particles are used for probe/DNA hybrid capture. PCR is
then applied to amplify the captured gDNA fragments [16, 40].
5.1.2. Clonal amplification and cyclic-array sequencing
5.1.2.1. Roche/454 (454 GS FLX Titanium/454 GS Junior) sequencing-by-synthesis; single-nucleotide
addition (SNA)
Once the library is ready, the second step toward sequencing with the Roche/454 instrumen-
tation, includes an “emulsion PCR” (emPCR) for clonal amplification of the amplicons already
produced. During emPCR, the DNA sequences are converted into single strands under alkali
conditions and captured on beads, in a unique single-stranded molecule per bead fashion.
Then, they get mixed with oil and aqueous buffer to create a system of droplets inside of whom
clonal PCR amplification takes place.
Once this step takes place, the beads containing the amplicons are placed into the wells of a
PicoTiter Plate (PTP) for a pyrosequencing reaction. During pyrosequencing, only one out of
the set of four different nucleotides or dNTPs (dATPαS, dTTP, dGTP, dCTP), is added into the
PTP, in each round. A series of enzymatic reactions, between enzymes and their substrates
(ATP sulfurylase, luciferase, luciferin, DNA polymerase and adenosine 5’ phosphosulfate;
APS) leads to the release of inorganic pyrophosphate (PPi) only when a specific dNTP is
incorporated. The release of PPi transforms ATP which drives luciferin into oxyluciferin that
emits visible light.
The light emitted is viewed by a charge-coupled diode (CCD) camera and translated into a
single peak per base incorporated, with a computer software. More than one nucleotide may
be incorporated per cycle, in the presence of homo-polymeric sequences (consecutive runs of
the same base). When this happens, light of equal amount to the number of the nucleotides
added, is emitted, resulting to an analogously higher peak.
Each time, the un-incorporated bases are degraded by apyrase. Subsequently, another set of
dNTPs is released one by one, in the reaction system and another pyrosequencing round is
performed.
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Many studies, utilizing Roche NGS platforms, GS FLX Titanium and GS Junior, for HLA typing
have been conducted so far. The comparative advantages this technology offers, over the rest
of its kind, are the long sequence reads (around 400 up to maximum 1000 amplicons), which
capture critical phase information of nearby DNA variants, and also the speed in which a
complete run is performed (10–24 h), depending of course on which machine is used.
The 454 GS FLX Titanium is capable of providing up to 1 million (M) reads per run depending
on the sequencing protocol, while the bench top format 454 GS Junior provides around 0.1 M
reads.
Despite the advantages of long reads and rapidity of the technique, there are several inborn
disadvantages. These include, high cost of pyrosequencing reagents, high error rate in case of
homo-polymers (typically more than six), and emPCR, the latest being a challenging reaction
that if semiautomated could reduce manpower. Insertion mutations are the most common
error type, followed by deletions [16, 29, 34, 35, 38–40, 43–45].
5.1.2.2. Illumina (MiSeq and MiniSeq) sequencing-by-synthesis; cycling reversible terminator (CRT)
Illumina utilizes a different sequencing-by-synthesis approach called CRT. During clonal
amplification, instead of emPCR, this system incorporates a glass slide with lanes (flowcell).
High density of primers complementary to a sequence of the adapters of the fragmented DNA
amplicons, are already attached to the slide where sequencing is later performed. Through a
process called clustering each fragment is isothermally amplified to create a cluster of clonally
amplified fragments, in a process called bridge amplification.
After amplification sequencing begins with the binding of the first sequencing primer on each
fragment of every cluster and its subsequent extension to produce the first read. All four dNTPs
are fluorescently tagged and compete with each other for addition to the growing chain. Once
a nucleotide that is complementary to the original sequence is incorporated, a washing step
removes all unbound nucleotides and a light signal of characteristic wavelength and intensity
is emitted. This signal that differs between the dNTPs is captivated by a CCD camera and
recorded by the computer [40].
The fluorescent molecule of each nucleotide incorporated needs to be cleaved before continu-
ing with the second cycle, due to its reversible terminator chemistry, that will not allow further
nucleotides to be added on the extending sequence. Once the light signal of the incorporated
molecule is emitted and received by the camera, the dye is removed and the second cycle is
ready to begin after an additional washing step. The length of the read depends on the number
of sequencing cycles that are pre-determined by the user [38].
Illumina instruments are shortread sequencers in opposition to those of Roche/454. They
provide read lengths of as low as 25 bp until up to 300 bp, with many intermediate options.
The MiSeq and the most recent MiniSeq bench top solution both offer an option of 44–50 M
Paired End (PE) reads, more than enough for HLA typing of many samples in the same run,
and competent to the GS machines concerning runtime (13–24 h) (Goodwin_2016). PE reads
denoted that two distinct sequencing reads are performed, one from each end of the template
DNA fragments.
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CRT sequencing method overcomes the disadvantages of SNA, by only incorporating a single
nucleotide at a time, however as the sequencing reaction proceeds, the error rate of the machine
increases. This is due to incomplete removal of the continuous fluorescence signals, which lead
to higher background noise levels. Sequencing errors accumulate toward the read end, thus
longer reads, that can be trimmed, are preferred compared to shorter ones. Longer reads also
prevail due to more precise mapping on the reference genome.
The chemistry of Illumina analyzers is also more prominent to substitution errors, rather than
InDel errors, especially when the previously incorporated nucleotide is guanine (G).
Nevertheless, the vast amount of reads may provide increased depth of sequencing coverage
that tends to overcome the high error rate inherent in this technology [38, 40].
5.1.2.3. Thermo-Fischer (Ion PGM)
The Thermo-Fischer Ion instruments acquire a pH-mediated sequencing detection method.
The sequencing reaction is the previously described sequencing-by-synthesis SNA approach,
but the detection of the incorporated nucleotides is substantially different.
The addition of a new dNTP on the extending DNA strand involves the formation of a covalent
bond and the release of pyrophosphate and a positively charged hydrogen ion (proton). The
shift in the pH level is detected by an ion-sensitive layer with a sensor on the bottom of the
microwells of a semiconductor chip, where sequencing takes place.
There are different sequencing chips with increasing number of wells allowing for different
strategies to be applied. The read length ranges from 200 to 400 bp sequenced, and depending
on the chip as low as 0.4 M and as high as 5.5 M reads can be exported from a PGM run.
The breakthrough of this technique regards the non-need for optic devices which contribute
to increased error calling, lower speed, higher cost, and larger instrument size. Also, the
employment of unmodified nucleotides circumvents potential biases arising from their
incorporation. Another positive characteristic is the runtime ranging from 2 to7 h that
outweighs other competitors.
However, the same drawbacks of SNA sequencing-by-synthesis method that were addressed
previously, also apply here. These constitute higher InDel errors and difficulties during
homopolymer region (>6 bp) sequencing [40, 43, 46].
5.2. The third generation of sequencers (single-molecule sequencing)
While the development and optimization of second-generation sequencers is still ongoing, the
third generation, that analyzes single-molecule templates, without the need for DNA pre-
amplification, is already on the field.
They promise even lower cost-per-base, easier sample preparation from less amount of starting
gDNA material, significantly faster run times, simplified primary data analysis and longer
read lengths (hundreds of base pairs and more).
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Longer reads simplify sequence assembly and facilitate polymorphism analysis and complete
haplotype phasing, both especially important for accurate HLA typing and clarification of
phase ambiguities [16].
Also, no need for PCR step overrides any potential biases rising from AT-rich and GC-rich
target sequences, avoids incorporation of additional nonexisting variants due to PCR ampli-
fication errors and reduces template preparation time [38, 43].
We distinguish two platforms among them. These are Pacific Biosciences (RS II) and Oxford
Nanopore (MinION) [47].
5.2.1. Pacific biosciences (RS II)—single-molecule real-time (SMRT) sequencing
The Pacific Biosciences (PacBio) instruments utilize a flowcell with many individual transpar-
ent bottom wells (zero-mode waveguide wells; ZMW), each holding 20 zeptoliters (10−21 L).
SMRT technology uses short single-stranded (ss) hairpin adaptors (SMRTbell adaptors) that
ligate on the ends of the DNA fragments. This results in ssDNA regions at the ends, and double-
stranded DNA (dsDNA) regions in the middle of the fragments.
Size-selection follows in order to retain sequences of preferred length from as low as less than
3 kb, up to around 20 kb, according to the purpose of the experiment.
A unique phi29 DNA polymerase molecule anchored to the bottom of each well binds a single
DNA molecule and starts copying it. The labeled dNTPs incorporate one at a time. Upon
binding the fluorophore emits light visualized with a laser and a camera, then the dye is cleaved
and the polymerase may incorporate the next labeled dNTP. Each color change at every single
one of the wells captured by the camera corresponds to a different dNTP added to the
amplifying sequence.
Each template is sequenced multiple times in a circular fashion. These multiple passes are used
to generate a consensus read of insert, known as circular consensus sequence (CCS) [17, 38, 46].
Generally, the runtime and throughput of the instrument can be tuned by the user. Longer
templates require longer times in order to extract consistent results.
The method of PacBio template preparation lasts 4–6 h, much less time compared to the one
needed for completion of the corresponding procedure for second-generation sequencers. In
addition, there is no need for a PCR step as previously described, resulting in reduced biases
and errors. The turnover rate is also reduced, with runs of RSII instruments finishing within
4 h. The average read length is 10–15 Kb (20,000 bp), longer than any other second-generation
sequencer [43, 46].
The main drawback of this technique is the high error rate, due to the short interphase interval
between two nucleotide incorporation events. Most errors appear as stochastic events and are
not biased anyhow, thus repeated circular sequencing of each nucleotide many times, results
in higher coverage and improved accuracy, up to 99% [38].
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5.2.2. Oxford Nanopore (MinION)
MinION is a third-generation sequencer from Oxford Nanopore that uses a tiny bio-pore of
nanoscale in diameter, with an attached exonuclease.
The fragments of dsDNA are primed with two adapters, a leader and a hairpin, one at each
end. The hairpin adapter holds the two strands together in ssDNA conformation, while the
leader adapter directs the DNA through the exonuclease which cleaves each base and guides
it via the pore.
The concept is that the ssDNA molecule that passes through the α-hemolysin pore (αHL),
disrupts the continuous ionic flow applied along αHL. The disruption is detected by standard
electrophysiological techniques. The current modulation differs for each of the nucleotides that
goes through the pore, a property that assists in discriminating them. Ionic current is resumed
after each trapped nucleotide squeezes out of the pore.
This type of sequencing needs no polymerase enzyme, there is no need for DNA polymeriza-
tion and incorporation of nucleotides, no need for pH alteration detection. As all it needs is
just a molecule of ssDNA and two suitable adapters, one at each end, that help guide it through
the exonuclease and the pore, the cost of sequencing is substantially lowered.
Also, this way of sequencing is fluorescent-tag free, along with the pros that were described
before, concerning Thermo-Scietific’s Ion technology, although these two differ in concept.
Also, the avoidance of using enzymes like polymerase constitutes Nanopore sequencing more
reliable as it is less sensitive to temperature alterations during sequencing.
A drawback of this technique is the large error rate of up to 30%, mainly for InDel detection,
due to the ability of the technique to detect more than 1000 different signals originating from
variation in the nucleotides coming through the pore, especially when modified bases present
on native DNA are taken into account. Also homopolymers are difficult to recognize due to
the same feature of this technique [43, 46].
6. Conclusions
Usually, only exons 2 and 3 of HLA class I genes and exon 2 of HLA class II genes are assessed
for polymorphisms, while other parts of HLA genes are not, due to time and cost constraints.
Many databases, such as dbMHC, AFND, IMGT/HLA, and others [12, 48, 49] keep a record of
known HLA allelic sequences and track newly found polymorphisms. Most HLA allelic
sequences are maintained there as CDS or partial exonic regions. This way, 8-digit HLA typing
resolution, which is the ultimate goal, cannot be achieved.
To address this issue, complete genomic sequence analysis of all HLA exons, along with other
important HLA regulatory sequences and also other significant genes, must be performed.
The high-resolution HLA typing of NGS is advantageous compared with the existing PCR/
SSO, PCR/SSP, and PCR/SBT techniques, but infers limitations that seem impossible to
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overcome, the most important being their incapability of sequencing long enough fragments,
in order to confront without ambiguity the allele phasing issue [17].
This is important because HLA is a highly polymorphic region, therefore it is quite difficult to
determine which variants are associated with the final phenotype, the latest resulting from the
complete end-to-end haplotype, meaning all variants across the MHC and also other genomic
loci [16, 40].
The above issues, of HLA ambiguity and phasing multiple short-read fragments, are resolved
with third-generation sequencers able to analyze long-reads that cover entire intronic-exonic
regions of whole genes. Further optimization and gradually reducing the cost and error rates
of these sequencers will establish their dominance in the field of HLA typing.
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